title: Treatment of Helicobacter pylori infection 2012.
abstract: Helicobacter pylori resistance rates to antibiotics vary in different countries and even in different regions of the same country. Choice of treatment is strongly dependent on antibiotic resistance rates. In some countries, triple therapy with a proton-pump inhibitor, amoxicillin, and clarithromycin is still the best option, but eradication results fall short of what would be desired (90-95%) in countries with clarithromycin resistance >20%, bismuth-containing quadruple therapy, or nonbismuth sequential or concomitant therapies may then be the preferred option. Newer antibiotic regimens are awaited. Vaccination would be the best option, especially for developing countries, but little progress has been made in designing a vaccine.
authors.affiliation: Department of Gastroenterology, Medical Centre Rogaska, Rogaska Slatina, Slovenia.
authors.forename: Bojan
authors.initials: B
authors.lastname: Tepes
authors.forename: Anthony
authors.initials: A
authors.lastname: O'Connor
authors.forename: Javier P
authors.initials: JP
authors.lastname: Gisbert
authors.forename: Colm
authors.initials: C
authors.lastname: O'Morain
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001428:Bacterial Vaccines / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000235:genetics / Q000276:immunology; D006801:Humans
chemical_list: D000900:Anti-Bacterial Agents; D001428:Bacterial Vaccines